HC Wainwright Has Bullish Forecast for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at HC Wainwright boosted their FY2025 EPS estimates for Esperion Therapeutics in a research note issued to investors on Tuesday, January 13th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.15) per share for the year, up from their previous forecast of ($0.42). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q4 2025 earnings at $0.02 EPS, FY2026 earnings at $0.58 EPS and FY2027 earnings at $0.81 EPS.

A number of other equities research analysts have also issued reports on ESPR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Piper Sandler began coverage on shares of Esperion Therapeutics in a research report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price objective for the company. Citigroup reissued a “market outperform” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Finally, Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Esperion Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.20.

Esperion Therapeutics Price Performance

NASDAQ:ESPR opened at $3.13 on Thursday. The business’s 50-day moving average is $3.57 and its two-hundred day moving average is $2.66. The firm has a market capitalization of $748.26 million, a PE ratio of -6.26, a price-to-earnings-growth ratio of 6.60 and a beta of 1.04. Esperion Therapeutics has a 12 month low of $0.69 and a 12 month high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The company had revenue of $87.31 million for the quarter, compared to analyst estimates of $78.33 million.

Institutional Trading of Esperion Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ESPR. Two Seas Capital LP grew its holdings in Esperion Therapeutics by 43.6% during the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock worth $9,800,000 after acquiring an additional 3,024,104 shares in the last quarter. AIGH Capital Management LLC bought a new stake in Esperion Therapeutics in the third quarter valued at about $7,950,000. Royce & Associates LP acquired a new stake in Esperion Therapeutics during the third quarter valued at approximately $6,078,000. Marshall Wace LLP lifted its holdings in Esperion Therapeutics by 46.2% during the 2nd quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock worth $5,206,000 after buying an additional 1,679,294 shares during the last quarter. Finally, Integral Health Asset Management LLC acquired a new position in shares of Esperion Therapeutics in the 3rd quarter worth approximately $3,975,000. Institutional investors own 47.39% of the company’s stock.

Insider Activity

In other news, CFO Benjamin Halladay sold 7,337 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total transaction of $26,926.79. Following the completion of the transaction, the chief financial officer directly owned 467,525 shares in the company, valued at approximately $1,715,816.75. This represents a 1.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.70% of the stock is currently owned by insiders.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.